Chemed's Crossroads: A Tale of Two Businesses at the Jefferies Conference

CINCINNATI, OH – September 08, 2026 – Next week, when executives from Chemed Corporation take the stage at the Jefferies 2026 Healthcare Services and Technology Conference, they will be presenting a story of profound contrast. The company, a unique conglomerate listed on the NYSE, operates two seemingly unrelated, yet market-leading businesses: VITAS Healthcare, the nation's largest provider of end-of-life hospice care, and Roto-Rooter, the country's leading plumbing and drain service. While a standard investor presentation is on the agenda, the underlying narrative is anything but. Chemed arrives at this conference at a strategic crossroads, fueled by the soaring success of its healthcare arm and complicated by significant challenges facing its iconic home services brand.

A Story of Divergent Fortunes

Recent financial disclosures paint a vivid picture of two businesses on different trajectories. For the first half of 2026, VITAS Healthcare has been the engine of Chemed’s growth. In the second quarter alone, VITAS posted a remarkable 11.9% year-over-year increase in net patient revenue, reaching $443.3 million. This surge was driven by a 6.1% rise in its average daily census, which surpassed 24,000 patients for the first time, and a 9.0% jump in admissions. Perhaps most significantly for investors, VITAS appears to have successfully navigated a complex Medicare Cap billing issue that impacted its 2025 results, accruing only a minimal $500,000 limitation in the last quarter compared to $16.4 million the prior year. This operational dexterity has boosted the segment’s gross margin and led Chemed to raise its full-year earnings guidance, signaling strong confidence in its healthcare division's future.

In stark contrast, Roto-Rooter is navigating a much tougher environment. While still a dominant force in its industry, the segment’s growth has been tepid. Second-quarter revenue grew a modest 3.3% to $229.9 million, but profitability is under pressure. The segment's adjusted EBITDA margin fell by 77 basis points, a trend linked directly to a fundamental shift in its customer acquisition strategy. This divergence has been so pronounced that management has characterized 2026 as a "transition year" for the plumbing business, setting the stage for critical questions about its long-term place within the Chemed portfolio.

The Digital Drain on Roto-Rooter

The core of Roto-Rooter's current struggle lies in the evolving landscape of digital marketing. For years, the brand's household name recognition generated a substantial flow of organic, or "free," leads from online searches. However, recent changes to Google's search algorithms have disrupted this model. According to company reports, the percentage of paid leads has climbed from 54% to 59% in just one year, significantly increasing customer acquisition costs. This digital headwind is not unique to Roto-Rooter, but it poses a serious threat to the margin structure of a business built on high-volume service calls.

While Roto-Rooter continues to diversify its offerings—with excavation and general plumbing services showing stronger growth than its traditional drain cleaning—the reliance on costly internet advertising remains a primary concern. The company is still pursuing its proven strategy of acquiring franchise territories, such as the recent $12 million purchase in South Texas, to consolidate its market share. However, investors at the Jefferies conference will undoubtedly be listening for a more detailed strategy on how management plans to restore margin health and create a more sustainable lead generation model in this new digital era.

The Billion-Dollar Question: A Strategic Split?

The most significant question looming over Chemed’s presentation is one that management itself introduced earlier this year. During a first-quarter earnings call, executives openly discussed the possibility of a strategic review for Roto-Rooter, including a potential divestiture or tax-free spin-off. This admission has shifted the investment thesis for Chemed, moving it from a story of managing two disparate cash-flow streams to one of potentially unlocking shareholder value by separating them.

Analysts and investors will be looking for any update on this front. The logic for a split is compelling to some: a standalone VITAS, unburdened by Roto-Rooter's challenges, could command a higher valuation as a pure-play healthcare leader. The proceeds from a sale could be used to accelerate VITAS’s growth, pay down debt, or fund a more aggressive share repurchase program, building on the $3.47 billion the company has already returned to shareholders since 2007. The decision hinges on whether the after-tax proceeds and strategic flexibility gained from a divestiture would create more value than the steady, albeit currently challenged, cash flow that Roto-Rooter provides.

The Future of Care is VITAS's Tailwind

While the fate of Roto-Rooter dominates strategic discussions, the fundamental strength of VITAS Healthcare remains the bedrock of Chemed's value proposition. The hospice provider is perfectly positioned to benefit from powerful demographic tailwinds, as the aging U.S. population drives sustained demand for end-of-life care. With 48 years of experience and a presence in 15 states, VITAS is not just a market leader but a critical component of the healthcare infrastructure.

The company’s strategy involves more than just riding a demographic wave. It is actively expanding its physical footprint with new inpatient centers and offices in key states like Florida and Colorado. Furthermore, its commitment to providing care regardless of a patient's ability to pay, exemplified by the $12.9 million in charity care provided in 2025, underscores its deep community integration. The upcoming presentation will be an opportunity for Chemed to highlight how VITAS is innovating within this vital sector, balancing operational excellence with the profound human need it serves, solidifying its role as the undisputed leader in hospice care.